Literature DB >> 21934720

The impact of pharmacogenomics on the management of cardiac disease.

N L Pereira1, R M Weinshilboum.   

Abstract

Pharmacogenomics promises to help maximize efficacy and minimize adverse drug reactions. It could have a significant impact on the treatment of cardiovascular disease, the leading cause of death in the United States. The past decade has seen pharmacogenomics move from study of a candidate gene to genome-wide approaches, with the development of a series of pharmacogenetic tests. However, many barriers need to be overcome for cardiovascular pharmacogenomics to have its promised clinical impact.

Entities:  

Mesh:

Year:  2011        PMID: 21934720      PMCID: PMC3912556          DOI: 10.1038/clpt.2011.187

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

Review 2.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

3.  A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

Authors:  Stephen B Liggett; Jeanne Mialet-Perez; Surai Thaneemit-Chen; Stewart A Weber; Scott M Greene; Danielle Hodne; Bradley Nelson; Jennifer Morrison; Michael J Domanski; Lynne E Wagoner; William T Abraham; Jeffrey L Anderson; John F Carlquist; Heidi J Krause-Steinrauf; Laura C Lazzeroni; J David Port; Philip W Lavori; Michael R Bristow
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-14       Impact factor: 11.205

4.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

5.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

  5 in total
  5 in total

Review 1.  Contemporary strategies in the diagnosis and management of heart failure.

Authors:  Shannon M Dunlay; Naveen L Pereira; Sudhir S Kushwaha
Journal:  Mayo Clin Proc       Date:  2014-03-29       Impact factor: 7.616

Review 2.  Genotype-based clinical trials in cardiovascular disease.

Authors:  Naveen L Pereira; Daniel J Sargent; Michael E Farkouh; Charanjit S Rihal
Journal:  Nat Rev Cardiol       Date:  2015-05-05       Impact factor: 32.419

Review 3.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Authors:  Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-02       Impact factor: 13.820

Review 4.  Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.

Authors:  QiPing Feng; Russell A Wilke; Tesfaye M Baye
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

5.  Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine.

Authors:  G Farrugia; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  2013-03-11       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.